Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00655044
NCT00655044
Completed
Not Applicable

Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus

Novo Nordisk A/S1 site in 1 country3,637 target enrollmentMay 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventionsinsulin detemir
Drugsinsulin detemir

Overview

Phase
Not Applicable
Intervention
insulin detemir
Conditions
Diabetes
Sponsor
Novo Nordisk A/S
Enrollment
3637
Locations
1
Primary Endpoint
HbA1C
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
January 2008
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Type 1 diabetes
  • •Type 2 diabetes
  • •Candidates of use of a basal insulin as part of their diabetes regimen

Exclusion Criteria

  • •Unwilling to adhere to therapy or follow up
  • •Pregnancy

Arms & Interventions

Type 1 and type 2 diabetes patients

Intervention: insulin detemir

Outcomes

Primary Outcomes

HbA1C

Time Frame: after 12 weeks

Secondary Outcomes

  • Safety(during treatment)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT00704223Novo Nordisk A/S619
Completed
Not Applicable
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 TreatmentDiabetesDiabetes Mellitus, Type 2
NCT00696995Novo Nordisk A/S509
Completed
Not Applicable
Observational Study to Evaluate the Safety of Levemir® in DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
NCT00706017Novo Nordisk A/S2,282
Completed
Not Applicable
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix InsulinDiabetesDiabetes Mellitus, Type 2
NCT00775736Novo Nordisk A/S611
Completed
Not Applicable
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
NCT00700765Novo Nordisk A/S1,531